Skip to content

Regeneron target raised to $400 by Barclays on 1Q, launch strength

May 6, 2017

Barclays raised its price target on Regeneron Pharma (NASDAQ: REGN) to $400.00 (from $375.00) while maintaining a Equalweight rating, following the company’s first quarter earnings report.

Analyst Geoff Meachem notes the company produced revenues above consensus, but missed on earnings per share print, as investors focus on the strong Dupixent launch.


From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: